Tarrant County Community College Institutional Review Board Full Committee Reviewer's Checklist

IRB#:	Researcher:			
Title:			Revi	iewer:
ни	MAN RE	SEARCH	I PROTE	CTIONS - ADMINISTRATIVE CHECKLIST
Required Signatures Provided	YES	NO		
Consent Document(s) Provided	YES	NO	N/A	
Recruitment Material Included	YES	NO	N/A	
Data Collection Instrument Included	YES	NO	N/A	
Protocol Provided	YES	NO	N/A	
Special Populations Identified	YES	NO	N/A	If yes, Vulnerable Populations form(s) required
Source of Funding Identified	YES	NO		
Human Subjects section of Federal Grant Application/Proposal Provided	YES	NO	N/A	If federally funded, a copy of the "Human Subjects" section of funding proposal is required
Permission Letters	YES	NO	N/A	If research is conducted at non-TCCD site, additional paperwork is required

ADMINISTRATIVE COMMENTS

ADMINISTRATIVE QUESTIONS/NOTES (Questions and notes directed to the committee.)

MAJOR CONCERNS (Ethical concerns,	risk/benefit issues,	subject capacity,	consent issues,	privacy and
	confidentiality iss	sues.)		

MINOR ISSUES (Typographical errors, grammar, pagination, and/or required UCI template language missing
from consent.)

REVIEWERS:

A. Please review the federal criteria for IRB approval and indicate whether the research meets each criterion by checking the appropriate box. List any concern that you would like communicated to the researcher in the corresponding comment box.

	CRITERIA FOR IRB REVIEW AND APPROVAL				
			COMMENTS or JUSTIFICATION (required)		
1	The IRB has the expertise needed to review this research.	YES NO			
2	I, the IRB reviewer, have a conflict of interest on this protocol.	YES NO			
3	The statement of purpose/hypothesis is adequate.	YES NO			
4	Study personnel appear appropriate and qualified.	☐ YES ☐ NO			
5	The study procedures in the narrative match the consent document(s).	☐ YES ☐ NO ☐ N/A			
6	The risks described in the narrative adequately cover all of the study risks.	YES NO			
7	The risks described in the narrative are consistent with the consent document.	☐ YES ☐ NO ☐ N/A			
Risk	Risk*/Benefit Assessment				
8	Risks to subjects will be minimized by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to	YES NO			

	risk.		
	Risks to subjects will be minimized,		
9	whenever appropriate, by using		
	procedures already being performed	☐ YES ☐ NO	
	on the subjects for diagnostic or	∐ N/A	
	treatment purposes.		
	Risks to subjects are reasonable in		
	relation to both:		
	 anticipated benefits, if any, 		
	to subjects; and		
10	the importance of the	☐ YES ☐ NO	
	knowledge that may		
	reasonably be expected to		
	result.		
Cubi			
Sub	ject Selection		
	Selection of subjects is equitable in		
11	relation to the purposes of the	YES NO	
	research and the setting in which		
	the research will be conducted.		
	Selection of subjects is appropriate		
4.0	(i.e., inclusion/exclusion criteria)		
12	based on the research and the	☐ YES ☐ NO	
	setting in which the research will be		
	conducted.		
_	The recruitment process will		
13	minimize the potential for undue	☐ YES ☐ NO	
	influence or coercion.		
	Compensation - neither the amount		
	of payment nor the proposed		
14	method and timing of disbursement	☐ YES ☐ NO	
	is coercive or presents potential for		
	undue influence.		
	Recruitment materials are	☐ YES ☐ NO	
15	appropriate	∐ N/A	
	арргорписс		
Sub	ect Protections		
	The research plan makes adequate		
16	provisions to protect the privacy of	YES NO	
	subjects.		
	The research plan makes adequate		
17	provisions to maintain the	YES NO	
	confidentiality of data.		
	The research does involve subjects		
	likely to be vulnerable to coercion or	☐ YES ☐ N/A	If Vulnerable Populations are involved,
4.0	undue influence, such as children,	<u> </u>	additional forms are required.
18	prisoners, pregnant women,		·
	mentally disabled persons or		
	economically or educationally		

	disadvantaged persons.						
	If YES, the research plan does [include additional safeguards to protect their rights and welfare.	YES N/A] NO				
	* Risks include possible physical, psycholo	ogical, econ	omic, so	ocial and l	gal harms.		
B. 1	Risk Assessment:						
	Virtually no risk [Exempt Registration	on]+					
	If research qualifies as Exempt, prov	vide the cate	egory(ie	rs): _			
	No more than Minimal Risk [Expedit	ted review]] +				
	If research qualifies as Expedited pro	ovide the co	ategory('ies):			
	☐ Greater than Minimal Risk [Full Com	nmittee revi	iew]				
†Ple	ase provide a brief rationale for your risk a	assessment	- Exem	pt or Expe	dited review		
C. 1	Informed Consent Process:						
	Informed Consent Process: ase review and confirm the circumstances of	f the conse	nt proce	ess. Next,	onfirm the pre	esence of all app	icable
Plea eler	ase review and confirm the circumstances of ments of informed consent in the consent do	ocument (e	e.g., con	sent form,	information sl	heet, or verbal	
Plea eler tele	ase review and confirm the circumstances of ments of informed consent in the consent do phone script). List any concerns that you we	ocument (e	e.g., con	sent form,	information sl	heet, or verbal	
Plea eler tele	ase review and confirm the circumstances of ments of informed consent in the consent do phone script). List any concerns that you we nment box or in the open space below.	ocument (e ould like co	e.g., con ommuni	sent form, cated to t	information sl	heet, or verbal	
Plea eler tele	ase review and confirm the circumstances of ments of informed consent in the consent do phone script). List any concerns that you we nment box or in the open space below.	ocument (e	e.g., con ommuni	sent form, cated to t	information sl ne researcher i	neet, or verbal n the correspond	ling
Plea eler tele	ase review and confirm the circumstances of ments of informed consent in the consent do phone script). List any concerns that you was ment box or in the open space below. Circumstances of the consent will be documented by content of the appropriate signatures on the informed	ocument (e rould like co rcumstance obtaining	e.g., con ommuni	sent form, cated to t	information sl ne researcher i	heet, or verbal	ling
Plea eler tele com	ese review and confirm the circumstances of ments of informed consent in the consent do phone script). List any concerns that you we ment box or in the open space below. Circumstances of the consent will be documented by the document	ocument (e rould like co cumstance obtaining d	e.g., con ommuni	sent form, cated to the cated t	information sl ne researcher i	neet, or verbal n the correspond	ling
Plea eler tele com	Informed consent will be documented by consent form. The researcher will obtain legally effective informed consent of either the: Subject's legally authorized representations.	ocument (e rould like co rcumstance obtaining d	e.g., con ommuni es of Cor	sent form, cated to the cated t	information sl ne researcher i	neet, or verbal n the correspond	ling
Plea eler tele com	Informed consent will be documented by a the appropriate signatures on the informed consent form. The researcher will obtain legally effective informed consent of either the: Subject Subject's legally authorized representations of consider whether or not to participate.	cocument (e	e.g., con ommuni es of Cor	sent form, cated to the cated t	information sl ne researcher i	neet, or verbal n the correspond	ling
Plea eler tele com	Informed consent will be documented by consent form. The researcher will obtain legally effective informed consent of either the: Subject Subject's legally authorized representations of the prospective subject sufficient opportunity	ocument (e	e.g., con ommuni es of Cor	sent form, cated to the sent NO N/A NO	information sl ne researcher i	neet, or verbal n the correspond	ling
Plea eler tele com	Informed consent will be documented by a the appropriate signatures on the informed consent form. The researcher will obtain legally effective informed consent of either the: Subject Subject Subject's legally authorized representations of consent provide the prospective subject sufficient opportunity consider whether or not to participate. The circumstances of consent minimize the	ocument (erould like controlled) countrolled countroll	e.g., con ommuni es of Cor YES YES	sent form, cated to the cated t	information sl ne researcher i	neet, or verbal n the correspond	ling

	legal rights.		
7	No information will be provided to the subject that releases or appears to release the researcher, the sponsor, the institution or its agents from liability for negligence.	YES NO	
8	The subject or the subject's surrogate decision maker will sign and date the informed consent form.	YES NO	
9	A copy of the informed consent document will be given to the person signing the form.	YES NO	
	THE CONSENT DOCUMENT/PROCESS WILL		COMMENTS
1	Explain the purpose of the research.	YES NO	
2	Disclose that the study involves research.	YES NO	
3	Explain the expected duration of the subject's participation.	YES NO	
4	Describe the procedures to be followed.	YES NO	
5	Identify any procedures that are experimental.	YES NO	
6	Describe any reasonably foreseeable risks or discomforts to the subject.	YES NO	
7	Describe any benefits to the subject or to others which may reasonably be expected from the research.	☐ YES ☐ NO	
8	Disclose appropriate alternative procedures or courses of treatment, if any that might benefit the subject.	YES NO	
9	Disclose the extent, if any, to which confidentiality of records identifying the subject will be maintained.	YES NO	
10	Includes a statement explaining whom to contact for answers to pertinent questions about the research and about the research subjects' rights.	YES NO	
11	Explain whom to contact in the event of a research-related injury to the subject.	YES NO	
12	Disclose that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled and that the subject may discontinue participation at any time without penalty or loss of benefits, to which the subject is otherwise entitled.	☐ YES ☐ NO	

	Additional Elements of Inforn	ned Consent, as ap	propriate
	THE CONSENT PROCESS WILL		COMMENTS
13	Choose one of the following: The approximate number of subjects involved in the study is not important in making a decision to participate in research. Explain the approximate number of subjects involved in the study (# at TCCD / total # for all study sites).	☐ YES ☐ NO	
14	Choose one of the following: The risk profile of all research-related interventions is well known and the research involves no investigational drugs or devices. Disclose that the particular treatment or procedure may involve risks to the subject which are currently unforeseeable.	☐ YES ☐ NO	
15	Choose one of the following: The research excludes women of child bearing potential and pregnant women. The risk profile of all research interventions or interactions on embryos and fetuses is well known. Disclose that the particular treatment or procedure may involve risks to the embryo or fetus, if the subject is or may become pregnant, which are currently unforeseeable.	☐ YES ☐ NO	
16	 Choose one of the following: □ There are no costs to the subject that may result from participation in the research. □ Disclose additional costs to the subject that may result from participation in the research. AND □ Disclose study compensation. 		
17	Choose one of the following: There are no anticipated circumstances under which the subject's participation will be terminated by the researcher without regard to the subject's consent. Disclose anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent.	☐ YES ☐ NO	

18	 Choose one of the following: There are no adverse consequences (physical, social, economic, legal or psychological) of a subject's decision to withdraw from the research. Disclose the following information: The consequences of the subject's decisions to withdraw from the research. The orderly termination of participation by the subject. 	☐ YES ☐ NO	
19	Choose one of the following: Significant new findings during the course of the research which may relate to the subject's willingness to continue participation are unlikely. Include a statement that significant new findings developed during the course of the research, which may relate to the subject's willingness to continue participation will be provided to the subject.	☐ YES ☐ NO	
20	Choose one of the following: The research involves no more than minimal risk and there is not even the appearance of a financial conflict of interest. Disclose that that no one on the study team has a disclosable financial interest in the outcome of this study. Disclose that a member of the study team personal financial interest in either the Sponsor or another interested entity. The nature of this financial interest and the design of the study have been reviewed by the Office of Grants Development and Compliance and they determined that the investigator's financial interests would not compromise the quality or reliability of the study.	☐ YES ☐ NO	
	IRB Recommendation: Approve Minor Changes	Not Met	
	☐ Tabled to full Committee☐ Disapprove		

Ε.	IRB Review cycle: 12 mos. 6 mos.* 0ther*:
*	Please provide a rationale below if recommended review cycle is less than 12 months.
<u>Ac</u>	lditional Comments [optional]:
Re	viewer's Signature:
Da	ite:

Note: The information provided on this form may be preliminary and may not necessarily reflect the discussion and final decision and/or recommendation of the full IRB committee.